INTS

INTS

Intensity Therapeutics Inc. Common stock

$0.320+0.000 (0.000%)

Preço em tempo real

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$0.320

Máximo

$0.320

Mínimo

$0.320

Volume

2.73M

Fundamentos da empresa

Estatísticas de negociação

Notícias relacionadas

PR Newswire

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and...

Ver mais
Intensity Therapeutics, Inc. Announces Pricing of Public Offering
PR Newswire

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and...

Ver mais
Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
PR Newswire

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and...

Ver mais
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study
PR Newswire

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...

Ver mais
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting